Catalyst Wire Dossier Catalyst Wire Dossier

Nal-IRI (Nanoliposomal irinotecan)

nanoliposomal irinotecan · Ipsen
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Nal-IRI (Nanoliposomal irinotecan), covering 2025-07-01 to 2025-07-01. Get the full timeline:

Most recent: Clinical Trial Update: Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer [Phase 1]

See pricing